The automatic tube labelling system market is driven by advancements in automation and increasing demand across industries like pharmaceuticals and diagnostics. These systems enhance efficiency and accuracy in labeling.
The automatic tube labelling system market is driven by advancements in automation and increasing demand across industries like pharmaceuticals and diagnostics. These systems enhance efficiency and accuracy in labeling.
The net worth of the irritable bowel syndrome treatment market registered a valuation of US$ 2,744.9 million in 2019. In 2024, the net valuation of the market is estimated to be US$ 4,076.1 million. The demand for irritable bowel syndrome treatment services is poised to evolve with a CAGR of 8.7% between 2024 and 2034. By the end of the forecast period, the net worth of the irritable bowel syndrome treatment industry is expected to be around US$ 9,355.4 million.
Nutrition-based methods for the treatment of irritable bowel syndrome are gaining more traction in recent years and are expected to propel the global market at a lucrative CAGR in the coming days. According to market estimates by Fact.MR, the global irritable bowel syndrome industry, including treatment therapies, could witness a year-on-year growth rate of 8.7% during this period.
Key Takeaways from the Global Irritable Bowel Syndrome Treatment Market Study Report
“Research and better understanding about the role of gut microbiomes in irritable bowel syndrome has shifted the focus of patients as well as market players on IBS nutritional therapies, “ says an analyst.
For More Insights into the Market, Request a Sample of this Report:https://www.factmr.com/connectus/sample?flag=S&rep_id=9520
Leading Players Driving Innovation in the Irritable Bowel Syndrome Treatment Market
Takeda Pharmaceutical Company Limited; Pfizer, Inc.; Abbott Laboratories; Novartis AG; AstraZeneca PLC; Ironwood Pharmaceuticals Inc. and Allergan Plc; Bausch Health Companies Inc.; GlaxoSmithKline, Plc.; Lexicon Pharmaceuticals, Inc.; Sucampo Pharmaceuticals, Inc.
Competitive Landscape for Irritable Bowel Syndrome Treatment Market Players
Access to irritable bowel syndrome treatment services has also been made possible by the continuous growth and expansion of the global healthcare infrastructure. In order to serve a wide range of patients needing specialist treatment for digestive health, providers are strategically placing themselves in different locations. So, the overall market is anticipated to diversify further in the coming days, resulting in higher competition and rivalry.
Recent Developments by the Irritable Bowel Syndrome Treatment Industry Participants
In March 2021, Bausch Health Companies Incorporation introduced GastroHub for advanced irritable bowel syndrome treatment providers. It is an instructional website created with knowledge about treating IBS-D and HE in mind for assisting physicians and nurse practitioners.
In March 2022, the Prescription Digital Therapeutics (PDT) business metaMe Health and Indegene collaborated to develop and introduce Regulora as a therapy for irritable bowel syndrome (IBS)-related abdominal discomfort. Indegene is a technology-driven healthcare solutions provider that is aiming to enter the IBS treatment after developing Regulora therapy.
In 2022, the biopharmaceutical firm Ardelyx disclosed the introduction of IBSRELA, which is the first and only NHE3 inhibitor specifically designed to treat adult cases of irritable bowel syndrome with constipation (IBS-C). IBSRELA is the first such medicine by Ardelyx, which was authorized by the US Food and Drug Administration (USFDA) in April 2022.
Irritable Bowel Syndrome Treatment Market News:
Get Customization on this Report for Specific Research Solutions: https://www.factmr.com/connectus/sample?flag=S&rep_id=9520
More Valuable Insights on Offer:
Fact.MR, in its new offering, presents an unbiased analysis of the global irritable bowel syndrome treatment market, presenting historical data for 2019 to 2023 and forecast statistics for 2024 to 2034.
The study reveals essential insights on the basis of the product type, indication, distribution channel, and region. By product type, the market includes fiber supplements, anti-diarrheal medications, anticholinergic and antispasmodic drugs, antidepressants, antibiotics, alosetron, lubiprostone, linaclotide, and NHE3 inhibitors. In terms of indication, the industry is segmented into IBS with constipation, IBS with diarrhea, and IBS with alternating constipation and diarrhea. The distribution channels for IBS treatments include hospital pharmacies, retail pharmacies, drug stores, online pharmacies and stores, hypermarkets and supermarkets, and other distribution channels. Geographically, the market is analyzed across North America, Europe, Latin America, East Asia, South Asia & Oceania, and the Middle East & Africa (MEA).
Check out More Related Studies Published by Fact.MR Research:
The global dysphagia supplement market size is estimated to be valued at US$ 1,430.6 million in 2024. The market is anticipated to develop at a CAGR of 7.1%, reaching a value of US$ 2,843.0 million by 2034. The dysphagia supplement industry is growing as a result of the rising prevalence and awareness of the condition.
The projected worth of the global dengue testing market is US$ 681.9 million in 2024. With a CAGR of 6.1% throughout the projected period and is anticipated to attain US$ 1,232.8 million by 2034.
The global immuno-oncology market size is estimated to have a value of US$ 24.17 billion in 2024. The market is expected to register a stirring CAGR of 16.5% from 2024 to 2034. By the end of the forecast period, the market size is expected to be worth US$ 111.64 billion.
The global biobetter market size is calculated at US$ 66.31 billion for 2024 and is forecast to reach US$ 150.75 billion by 2034, with a projected CAGR of 8.6% from 2024 to 2034.
The global automatic tube labelling system market size is estimated at US$ 69.6 million in 2024 and is forecasted to reach US$ 109.1 million by the end of 2034. Worldwide demand for automatic tube labelling systems is forecasted to rise at a CAGR of 4.6% from 2024 to 2034.
Irritable bowel syndrome (IBS) is a common gastrointestinal disorder characterized by symptoms such as abdominal pain, bloating, and changes in bowel habits, including diarrhea and constipation.
CAGR stands for Compound Annual Growth Rate. It is a useful measure to understand the mean annual growth rate of an investment over a specified time period, assuming the investment grows at a steady rate.
Explore more articles in the Research Reports category
